リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Correlation of Antidepressant Use and Symptom Time Period in Dream Enactment Behaviors」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Correlation of Antidepressant Use and Symptom Time Period in Dream Enactment Behaviors

SUMI Yukiyoshi 10772923 0000-0001-6775-0883 KADOTANI Hiroshi 90362516 0000-0001-7474-3315 OZEKI Yuji 90303768 0000-0002-9516-0941 滋賀医科大学

2021.11.19

概要

It is with great interest that we read the article by Otaiku that investigated the effects of dream content on future symptom exacerbation.1 In line with their study, we would like to highlight three concerns.

 First, the incidence of dream enactment behaviors (DEBs) due to antidepressant intake should be considered. Antidepressants have been reported to cause DEBs.2 Considering that patients with Parkinson's disease (PD) are commonly comorbid with depression, the PD with aggressive dreams group in this study may include patients with DEBs caused by antidepressants, suggesting that depression comorbidity may be a confounding factor. Although according to the article, "all patients were at an early stage and unmedicated at baseline," neither the study nor the Parkinson's Progression Marker Initiative database describes the rate of depression or the use of antidepressants. It would be helpful to specify the antidepressants use to resolve this concern.

 Second, clonazepam use may lead to cognitive decline. Otaiku reported that in patients in the PD with aggressive dreams group, cognitive function was significantly impaired. Since patients with rapid eye movement (REM) sleep behavior disorder (RBD) are often injured, it is necessary and appropriate to start medications to relieve DEBs to prevent injury. However, clonazepam, commonly used in DEB treatment, cause sedative side effects and impair cognitive function.3 The author could address the impact of medications on cognitive impairment by describing the use of DEB treatment at baseline and follow-up.

 Third, the fluctuation in the symptoms of DEBs in PD patients was not considered. DEBs in patients with idiopathic RBD or PD with RBD may diminish over time. Our previous study found that in patients with idiopathic RBD, the frequency of DEBs peaked 2–8 years after RBD onset and decreased afterwards.4 Moreover, it was reported that RBD symptoms improved after three years of follow-up in a quarter of PD patients with RBD.5 The DEBs seem to exacerbate for a while and then lessen in intensity, rather than worsen over time. Therefore, when assessing the dream experience of patients with PD, there are three possible situations: those who never had aggressive dreams; those currently experiencing aggressive dreams; those who previously experienced aggressive dreams but are not currently experiencing them. In the RBD screening questionnaire (RBDSQ), the period of aggressive dream experience is not defined (e.g., the last six months). Therefore, patients who answered "No" to item 3 of the RBDSQ, stating that "My dreams frequently have an aggressive or action- packed content," may include those who never experienced aggressive dreams before, and those who once experienced aggressive dreams but now no longer do. It remains to be determined whether the group whose aggressive dreams have disappeared should be included in the "without aggressive dreams" group or indicated separately. However, it is essential to clarify the time frame in the survey and obtain information on previous symptom occurrences. The proportion of those who have never experienced aggressive dreams before or whose aggressive dreams have disappeared in the PD without aggressive dreams group should be described.

参考文献

1. Otaiku AI. Dream content predicts motor and cognitive decline in Parkinson's disease. Mov Disord Clin Pract 2021; 8(7): 1041-1051. doi: 10.1002/mdc3.13318 [published Online First: 2021/10/12]

2. Ju YE, Larson-Prior L, Duntley S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med 2011; 12(3): 278-283. doi: 10.1016/j.sleep.2010.07.022 [published Online First: 2011/02/15]

3. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6(1): 85-95. [published Online First: 2010/03/03]

4. Sumi Y, Matsuo M, Nakabayashi T, et al. Changes in the symptom frequency of rapid eye movement sleep behavior disorder according to disease duration. Sleep Science Practice 2017; 1(16): 1–6. doi.org/10.1186/s41606-017-0017-4 [published Online First: 2017/08/06]

5. Figorilli M, Marques AR, Vidal T, et al. Does REM sleep behavior disorder change in the progression of Parkinson's disease? Sleep Med 2020; 68: 190-198. doi: 10.1016/j.sleep.2019.12.013 [published Online First: 2020/02/12]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る